Karyopharm Therapeutics Total Current Liabilities

As of the most recent data (June 2026), KPTI shows a total current liabilities of $130M. That compares with $99M in the prior-year period — up 35.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KPTI's total current liabilities is now $130M (was $99M) — a 35.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Karyopharm Therapeutics is outperforming or lagging.

Tracking KPTI's total current liabilities over time shows whether Karyopharm Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $130M That compares with $99M in the prior-year period — up 35.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Karyopharm Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $130M) with ownership activity and broader fundamentals.

Karyopharm Therapeutics's total current liabilities is $130M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.